VerbatimParliament, as it happens

Donanemab and Lecanemab

Asked by Freddie van MierloLiberal DemocratDepartment of Health and Social CareTabled Answered 19 March 2026UIN 119738

The question

To ask the Secretary of State for Health and Social Care, when he expects NICE to publish the outcomes of the appeals on its final draft guidance on donanemab and lecanemab.

Answered by Dr Zubir Ahmed

The appeals against the National Institute for Health and Care Excellence (NICE) recommendations on donanemab and lecanemab for the treatment of Alzheimer’s disease were heard by NICE’s independent appeal panel in January. The next steps of the appraisal will be subject to the outcome of the appeals, and NICE will update its stakeholders in due course.

Verbatim has judged this answer against the question that was actually asked — answered, partly answered, or evaded. Sign in to see the verdict →

Open this question in Verbatim →

Every written question, searchable

155,000 questions tabled since the election, with the answer each department gave — and the ones still unanswered, with the clock running. Free to search.

Search written questions →Read on Verbatim